The finding that CD147 knockdown may improve antitumor efficacy in patients with HER2-positive solid tumors provides a new strategy for constructing bispecific antibodies against CD147 and HER2 or adding other effective targets, which will be extremely significant for clinical tumor immunotherapy in the future. Here, ERBB2 is linked to neoplasm.